# Core-007

> **NIH NIH UL1** · UNIV OF MASSACHUSETTS MED SCH WORCESTER · 2020 · $712,919

## Abstract

This Optional Function Application directly addresses a major goal of the UMCCTS, specifically, to accelerate
the translation of basic discoveries into efficient solutions that improve human health. We will capitalize on
UMass’ international reputation as a hub for noncoding RNA investigation and discovery to establish an
Integrative Biomarker Center (InBioC), that builds onto existing UMCCTS infrastructure by providing a
resource that enhances clinical research, enriches biomarker innovation, facilitates novel discovery, and builds
bridges throughout the broader UMass community. We expect that the expansion of novel, innovative, and
accessible biomarkers to a wider audience will enhance discoveries regarding human disease. Currently, the
UMMS High-Throughput Gene Expression/Biomarker Laboratory provides rapid, cost-effective biomarker
analyses and generates valuable data for a wide range of projects. Importantly, the lab is not static, and
technologies utilized evolve to remain cutting edge and scientifically impactful. We have provided some of the
largest data sets of noncoding RNAs in human populations and continue to develop novel tools in this area.
Utilizing this expertise, we will build out the laboratory as a central hub that will provide education, as well as
laboratory and virtual data to UMass investigators based on their scientific needs. To form these central
“connections”, the Integrative Biomarker Center (InBioC), will link data and groups through: Aim 1: Advance
the science of biomarker development. We will work with investigators to provide relevant and timely
supportive data such as proteomics, RNA, and phenotypic information. InBioC will 1a. Continue development
of cutting-edge platforms; 1b. Institute a “Seed Money” program to provide support for investigators to
generate needed data for programs, grants, and projects (discussed above); 1c. Provide education regarding
the data generated and technologies used, as well as in-laboratory internships for junior investigators; and 1d.
Create a virtual data repository that will allow data sharing and/or reanalysis. Aim 2: Facilitate the use of
biomarkers to understand disease and develop new therapies: This will be accomplished by: 2a. Close
collaboration with UMCCTS Informatics Component and UMCCTS BERD to support and assist with target
analyses and network development based on new and available data sets. This will ensure proper and
productive interpretation of often complex information; 2b. Close collaboration with biomarker development,
specifically with the UMCCTS Tissue Core and Biorepository, which will serve as a source of biomaterials for
investigators; and 2c. Outreach and close collaboration with the community, the Science Participation
Research Center (SPRC), and the 5 UMass Campuses.

## Key facts

- **NIH application ID:** 10183624
- **Project number:** 2UL1TR001453-05A1
- **Recipient organization:** UNIV OF MASSACHUSETTS MED SCH WORCESTER
- **Principal Investigator:** Katherine F. Luzuriaga
- **Activity code:** UL1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $712,919
- **Award type:** 2
- **Project period:** — → —

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10183624

## Citation

> US National Institutes of Health, RePORTER application 10183624, Core-007 (2UL1TR001453-05A1). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10183624. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*